Turin ALS Center – CRESLA

University of Torino

The Torino ALS Center (CRESLA) provides excellence both in basic and clinical research, while at the same time is a reference center for the care of ALS patients. It follows about 350 patients each year, both from its catchment area (the Piemonte region) and from throughout Italy.

Cresla_footer

The CRESLA, which has a diagnostic neuropathology laboratory and a molecular genetics laboratory, is clinically based in the “Città della Salute e della Scienza” of Torino, the largest public hospital in Italy.

In the last decade, the CRESLA has participated to 5 large international randomized clinical trials on innovative drugs in ALS. The center is able to design and carry on both phase I-II and phase II trials, and includes a data manager and a statistical branch.

The centre has a multidisclinary group, with a daily ALS clinic, and utilizes the in-patient beds and the day hospital of the Department of Neuroscience. The centre includes a psychological and neuropsychological service. The centre has a neurophysiological service (EMG, motor evoked potentials) and collaborates with the Laboratory of Neuropathology and Neurobiology (located in the same Department) and the Laboratory of Molecular Biology and Genetics (located in a nearby hospital).

Contact
Location
University of Turin, Turin, Via Cherasco 15, 10126, Torino, Italy

Specialists

Adriano Chiò

Professor of Neurology

Adriano Chiò is professor of Neurology at the University of Torino, Italy

Adriano Chiò
Current trials
Recruiting
Phase iii

TUDCA-ALS (TUDCA)

Industry sponsored trial

TUDCA (tauroursodeoxycholic acid) is a small molecule that is being explored for its potential as a treatment for ALS

Read more
In preparation
Phase iii

PreLude (Lithium carbonate)

Platform trial arm

Within an innovative platform design study, we will evaluate the efficacy of lithium carbonate in UNC13a homozygous patients.

Read more
In preparation
Phase ii

Lighthouse (Triumeq)

Platform trial arm

Within an innovative platform design study, we will evaluate the efficacy of Triumeq, a therapy developed for treatment of HIV that has shown to slow progression in ALS

Read more
In preparation
Phase iii

iAdore (Oral edaravone)

Platform trial arm

Within an innovative platform design study, we will evaluate the efficacy of oral edaravone (TW001), a formulation that reduces oxidative stress

Read more